In this study, we demonstrated that LPA increased the proliferation and subsequent progression of the gastric cancer cells, which get abrogated into the functional level by both LPA receptor antagonists (Ki16425 and the LPAR2 receptor antagonist) and LPAR2 knockdown. Here, LPAR2 is linked to gastric cancer.